<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00515632</url>
  </required_header>
  <id_info>
    <org_study_id>DRF2593-307</org_study_id>
    <secondary_id>EudraCT No. 2007-002088-29</secondary_id>
    <nct_id>NCT00515632</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Treatment With Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy</brief_title>
  <acronym>BALLET</acronym>
  <official_title>A Randomized, Double-blind, Parallel-group, Placebo and Active Comparator (Pioglitazone)-Controlled Clinical Study to Determine the Efficacy and Safety of Balaglitazone in Patients With Type 2 Diabetes on Stable Insulin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rheoscience A/S</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rheoscience A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus is a metabolic disorder that is primarily characterized by insulin
      resistance, relative insulin deficiency, and hyperglycemia. People with type 2 diabetes are
      at high risk of many serious diabetic complications, including cardiovascular disease,
      blindness, nerve damage and kidney damage. Balaglitazone is a thiazolidinedione derivative
      that is being developed as an oral anti-diabetic drug to improve blood glucose control in
      patients with type 2 diabetes. The purpose of this study is to assess if additional treatment
      with balaglitazone in patients with type 2 diabetes on stable insulin treatment will improve
      blood glucose control and decrease the daily insulin dose compared to placebo, but with less
      impact on weight gain and oedema than pioglitazone (Actos®) 45 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c, fasting plasma glucose and 7-point plasma glucose profiles, weight gain, lower leg oedema and safety parameters.</measure>
    <time_frame>baseline, 4, 8, 12, 17, 21 and 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist and hip circumferences, plasmaNT-proBNP, ECG, body composition as measured by DXA, blood lipid profiles, plasma insulin</measure>
    <time_frame>baseline and 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">409</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Balaglitazone 10 mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Balaglitazone 20 mg per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone 45 mg per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Balaglitazone</intervention_name>
    <description>One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.</description>
    <arm_group_label>Balaglitazone 10 mg per day</arm_group_label>
    <arm_group_label>Balaglitazone 20 mg per day</arm_group_label>
    <arm_group_label>Pioglitazone 45 mg per day</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes mellitus, being diagnosed according to the 1999 WHO criteria for at
             least 3 months

          2. Age ≥ 18 years

          3. BMI ≥ 25.0 kg/m2

          4. HbA1c ≥ 7.0 %

          5. Treatment with insulin with stable dose of at least 30 U/day (± 4 U/day), for at least
             75 days

        Exclusion Criteria:

          1. Prior or current use of any PPAR-γ agonist

          2. Recent use (&lt; 3 months) of an investigational drug

          3. Pre-existing medical condition judged to preclude safe participation in the study

          4. Contraindication/intolerance to study medication

          5. Use of any drug which in the Investigator's opinion could interfere with the glucose
             level (e.g. systemic corticosteroids)

          6. Diagnosed or receiving medication for heart failure, NYHA I to IV

          7. Hospitalisation for a major CV event in the last 3 months, scheduled major CV
             intervention

          8. Uncontrolled treated/untreated systolic blood pressure &gt;180 mmHg and/or diastolic
             blood pressure &gt; 95 mmHg

          9. Known diabetic macular oedema

         10. Hematuria

         11. Serum creatinine &gt;130 μmol/l

         12. ALT, AST, total bilirubin or alkaline phosphatase ≥ 2.5 times the upper limit of
             normal

         13. Haemoglobin significantly (in the Investigators opinion, but not more than 1 mmol/L)
             below the lower limit of normal or haemoglobinopathy interfering with valid HbA1c
             assay

         14. Pregnancy, breast feeding or planning pregnancy or not using adequate contraceptive
             methods (adequate contraceptive measures are an intrauterine device or oral
             contraceptives)

         15. Mental incapacity, unwillingness, or language barrier precluding adequate
             understanding or cooperation

         16. Abuse of alcohol or drugs, or presence of any condition that in the Investigators
             opinion may lead to poor adherence to study protocols

         17. Cancer or any clinically significant disease or disorder, except for conditions
             associated to the type 2 diabetes, which in the Investigator's opinion could interfere
             with the results of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bente J Riis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nordic Bioscience Clinical Studies A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Multi-center</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2007</study_first_submitted>
  <study_first_submitted_qc>August 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2007</study_first_posted>
  <last_update_submitted>July 22, 2010</last_update_submitted>
  <last_update_submitted_qc>July 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bente Juel Riis, MD</name_title>
    <organization>Rheoscience A/S</organization>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus on Stable insulin therapy</keyword>
  <keyword>Balaglitazone</keyword>
  <keyword>Pioglitazone (Actos®)</keyword>
  <keyword>HbA1c</keyword>
  <keyword>Weight gain</keyword>
  <keyword>Oedema</keyword>
  <keyword>Fasting blood glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

